Two new approvals for Janssen’s Simponi Aria
US regulators have expanded the scope of Janssen Biotech’s Simponi Aria to include the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS).
Read More
Tag: AS
Final NICE yes for Novartis’ Cosentyx in ankylosing spondylitis
Guidelines from the National Institute for Health and Care Excellence recommend Novartis’ Cosentyx for treating active ankylosing spondylitis that has not responded well enough to conventional therapy.
Read More
Novartis plans head-to-head trial for Cosentyx and Humira
Novartis and Sandoz are to present new analyses indicating that their biologic Cosentyx could lead to higher responses than AbbVie’s anti-inflammatory super-blockbuster Humira in improving the signs and symptoms of ankylosing spondylitis and psoriatic arthritis.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
